ADIL
Adial Pharmaceuticals, Inc. (ADIL) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
No disclosed environmental intensity metrics or transition targets are provided, limiting evidence of peer-leading emissions management versus more transparent healthcare peers.
Zero reported R&D-to-revenue in the supplied metrics suggests limited innovation disclosure, which weakens visibility on lower-impact product development relative to peers.
The absence of reported environmental KPIs reduces comparability on waste, energy, and supply-chain stewardship, leaving ADIL closer to average disclosure peers than leaders.
No post-August 2025 filings or third-party sources were provided, so the assessment relies on limited metrics rather than verified environmental performance data.
Social
The provided data do not disclose workforce, patient, or product-safety indicators, which constrains evidence of stronger social management versus peers.
Zero stock-based compensation-to-revenue may indicate limited equity dilution, but it does not substitute for disclosed employee retention or culture metrics relative to peers.
No metrics are provided on diversity, training, or community impact, leaving ADIL without the transparent social disclosures seen at stronger-reporting peers.
Because social risk visibility is low, the company appears neither clearly advantaged nor structurally weaker than peers on the available evidence.
Governance
The supplied leverage metrics show debt-to-equity at zero and net debt-to-EBITDA below one, which suggests a relatively conservative balance-sheet structure versus leveraged peers.
However, the absence of board, audit, ownership, and control disclosures prevents confirmation of stronger governance practices relative to better-governed peers.
Zero stock-based compensation-to-revenue may reduce incentive complexity, but it also limits insight into executive alignment and compensation governance versus peers.
Overall governance remains only moderately positioned because the available data show balance-sheet discipline, yet lack the disclosure depth typical of stronger peers.
Overall Score
ADIL screens as a moderate ESG peer on the limited evidence provided, with conservative leverage offset by weak disclosure depth across environmental, social, and governance factors.
Score Driver: Limited ESG Disclosure Visibility Versus Peers
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Adial Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
